Innovus Pharmaceuticals Announces Successful Top Line Clinical Results From Sensum+(R) in Diabetic and Non-Diabetic Circumcised Men With Low Penile Sensitivity

 

Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) www.innovuspharma.com (OTCQB: INNV), a company focusing on the commercialization of over-the-counter (“OTC”) and consumer products for men’s and women’s health, vitality and respiratory diseases, today announced the Company’s top line results from its Sensum+® human survey use clinical trial in circumcised men with low penile sensitivity.

Results from the study showed statistically significant increase in all endpoints measured including:

1. 197% in penile sensitivity 2. 60% reduction in time for Masturbation Ejaculatory Latency Time (MELT) in diabetic men 3. Over 300% increase in satisfaction 4. Close to 275% increase in Partner’s Satisfaction

About the INNV-RPS1001-M Use Survey Trial

The clinical use survey study was developed to assess the effect of Sensum+® on penile sensitivity after 3 weeks of twice daily treatment

Pursuant to these clinical trials, the data indicate that Sensum+® was very well tolerated with no serious adverse events reported.

Sensum+® is a proprietary topical formulation specifically designed to increase penile sensitivity.

“We are thrilled about these results from the Sensum+® human use survey trial which we believe confirms that activity of the product and increase its commercial potential,” said Dr. Bassam Damaj, President & CEO of the Innovus Pharma. “Reduced penile sensitivity is a major concern to men and it is estimated to affect millions around the world,” continued Dr. Damaj.

About Sensum+® and Reduced Penile Sensitivity (RPS)

Sensum+® is a patented blend of essential oils and natural botanicals including rose oil, sweet almond oil, cinnamon bark oil, and other extracts. The main ingredient of Sensum+® (cinnamon oil) works by activating the Transient Receptor Potential A1 (TRPA-1) channels responsible for the heat and cold sensation of the skin and results in an increase of sensation that current users welcome and appreciate. The safety and efficacy of Sensum+® was evaluated in 2 post marketing survey studies in circumcised and non-circumcised men. A total of 382 men used Sensum+® twice daily for fourteen consecutive days followed by once daily for 8 weeks and as needed thereafter.

Reduced penile sensitivity is a major problem associated with many diseases such as hernia surgery, the use of anti-depressants, circumcision, multiple sclerosis and others. There are no approved products to treat RPS.

Read more at: Innovus Pharmaceuticals Announces Successful Top Line Clinical Results From Sensum+(R) in Diabetic and Non-Diabetic Circumcised Men With Low Penile Sensitivity

2015-11-20T15:01:24+00:00

About the Author: